See the DrugPatentWatch profile for Dabigatran
Dabigatran etexilate mesylate, marketed as Pradaxa, is an oral direct thrombin inhibitor used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, and to treat deep vein thrombosis and pulmonary embolism [1].
How does Pradaxa work?
Pradaxa functions by directly inhibiting thrombin, a key enzyme in the blood clotting cascade. Thrombin converts fibrinogen into fibrin, which forms the meshwork of a blood clot. By blocking thrombin's activity, dabigatran prevents clot formation [1].
When does the Pradaxa patent expire?
The patent landscape for Pradaxa is complex and involves multiple patents covering the drug substance, formulations, and methods of use. According to DrugPatentWatch.com, the earliest key patents for dabigatran etexilate began expiring around 2017, with later patents extending further. Specific patent expiry dates can vary by region and the type of patent [2].
What is the difference between dabigatran and other blood thinners?
Unlike warfarin, which requires regular monitoring of blood clotting levels, dabigatran does not necessitate routine blood tests. It also differs from other direct oral anticoagulants (DOACs) like rivaroxaban and apixaban by directly inhibiting thrombin, whereas the others are Factor Xa inhibitors [1].
Can biosimilars be made for Pradaxa?
Dabigatran etexilate is a small molecule drug, not a biologic. Therefore, the term "biosimilar" does not apply. Instead, generic versions of dabigatran etexilate can be developed and approved once patents and exclusivities expire, provided they demonstrate bioequivalence to the brand-name drug [3].
What are the risks associated with taking Pradaxa?
The most significant risk associated with Pradaxa, like other anticoagulants, is bleeding. This can range from minor bruising to life-threatening hemorrhages [1]. Other potential side effects include indigestion and nausea [1].
What is the clinical data on Pradaxa's effectiveness?
Clinical trials, such as the RE-LY study, demonstrated that dabigatran etexilate was non-inferior to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation, with a lower risk of intracranial bleeding [1].
Who makes Pradaxa?
Pradaxa is manufactured by Boehringer Ingelheim [1].
How is Pradaxa dosed?
The typical dosage for stroke prevention in non-valvular atrial fibrillation is 150 mg twice daily. Dosage adjustments are recommended for patients with impaired kidney function [1].
What happens if you miss a dose of Pradaxa?
If a dose of Pradaxa is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose. Two doses should not be taken at once [1].
Sources:
1. https://www.pradaxa.com/
2. https://drugpatentwatch.com/
3. https://www.fda.gov/